

Marisa H Miceli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3915960/publications.pdf>

Version: 2024-02-01

38
papers

1,785
citations

471371

17
h-index

330025

37
g-index

38
all docs

38
docs citations

38
times ranked

2581
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of targeted versus universal prophylaxis for the prevention of invasive fungal infections following lung transplantation. <i>Transplant Infectious Disease</i> , 2021, 23, e13448.	0.7	9
2	Mucormycosis. <i>Infectious Disease Clinics of North America</i> , 2021, 35, 435-452.	1.9	54
3	COVID-19-Associated Pulmonary Aspergillosis at an Academic Medical Center in the Midwestern United States. <i>Mycopathologia</i> , 2021, 186, 499-505.	1.3	8
4	Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e364-e374.	4.6	99
5	Invasive Fungal Disease in Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 761.	1.5	6
6	Diagnostic Performance of Bronchoalveolar Lavage (1,3)- β -D-Glucan Assay for <i>Pneumocystis jirovecii</i> Pneumonia. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 200.	1.5	2
7	Performance of Aspergillus Galactomannan Lateral Flow Assay on Bronchoalveolar Lavage Fluid for the Diagnosis of Invasive Pulmonary Aspergillosis. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 297.	1.5	13
8	Performance of the (1,3)-Beta-d-Glucan Assay on Bronchoalveolar Lavage Fluid for the Diagnosis of Invasive Pulmonary Aspergillosis. <i>Mycopathologia</i> , 2020, 185, 925-929.	1.3	11
9	The Aspergillus Lateral Flow Assay for the Diagnosis of Invasive Aspergillosis: an Update. <i>Current Fungal Infection Reports</i> , 2020, 14, 378-383.	0.9	14
10	Clinical mycology today: A synopsis of the mycoses study group education and research consortium (MSGERC) second biennial meeting, September 27-30, 2018, Big Sky, Montana, a proposed global research agenda. <i>Medical Mycology</i> , 2020, 58, 569-578.	0.3	1
11	Clinical characteristics and outcomes of invasive <i>Lomentospora prolificans</i> infections: Analysis of patients in the FungiScope registry. <i>Mycoses</i> , 2020, 63, 437-442.	1.8	41
12	Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia. <i>Mycopathologia</i> , 2020, 185, 299-306.	1.3	10
13	Invasive aspergillosis in patients following umbilical cord blood transplant. <i>Bone Marrow Transplantation</i> , 2019, 54, 308-311.	1.3	4
14	Clinical application of Aspergillus lateral flow device in bronchoalveolar lavage fluid of patients with classic risk factors for invasive pulmonary aspergillosis. <i>Mycoses</i> , 2019, 62, 1189-1193.	1.8	8
15	Treatment Failure of Isavuconazole in a Patient with Cryptococcosis. <i>Mycopathologia</i> , 2019, 184, 667-670.	1.3	6
16	Central Nervous System Infections Due to Aspergillus and Other Hyaline Molds. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019, 5, 79.	1.5	29
17	Infectious Complications After Umbilical Cord Blood Transplantation for Hematological Malignancy. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz037.	0.4	15
18	Testing the performance of a prototype lateral flow device using bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in high-risk patients. <i>Mycoses</i> , 2018, 61, 4-10.	1.8	15

#	ARTICLE	IF	CITATIONS
19	2042. Clinical Application of AspID PCR Alone and in Combination with Aspergillus Lateral Flow Device (AspLFD) in Bronchoalveolar Lavage (BAL) Fluid of Patients with Classic Risk Factors for Invasive Pulmonary Aspergillosis (IPA). <i>Open Forum Infectious Diseases</i> , 2018, 5, S595-S596.	0.4	0
20	Risk Factors and Outcomes of Invasive Fungal Infections in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Mycopathologia</i> , 2017, 182, 495-504.	1.3	28
21	Effect of underlying immune compromise on the manifestations and outcomes of group A streptococcal bacteremia. <i>Journal of Infection</i> , 2017, 74, 450-455.	1.7	5
22	Daptomycin nonsusceptible vancomycin resistant <i>Enterococcus</i> bloodstream infections in patients with hematological malignancies: risk factors and outcomes. <i>Leukemia and Lymphoma</i> , 2017, 58, 2852-2858.	0.6	20
23	<i>Aspergillus</i> Galactomannan for Diagnosing Invasive Aspergillosis. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1175.	3.8	17
24	Risk factors for subtherapeutic levels of posaconazole tablet. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2902-2905.	1.3	37
25	Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2355-2358.	1.3	30
26	<i>Mycobacterium marinum</i> remains an unrecognized cause of indolent skin infections. <i>Cutis</i> , 2017, 100, 331-336.	0.4	4
27	Diagnosis of Midwestern Endemic Mycoses. <i>Current Fungal Infection Reports</i> , 2016, 10, 87-95.	0.9	3
28	Pulmonary Blastomycosis in a Hematopoietic Cell Transplant Recipient. <i>Infectious Diseases in Clinical Practice</i> , 2016, 24, e71-e73.	0.1	6
29	Blastomycosis. <i>Infectious Disease Clinics of North America</i> , 2016, 30, 247-264.	1.9	114
30	Performance of lateral flow device and galactomannan for the detection of <i>Aspergillus</i> species in bronchoalveolar fluid of patients at risk for invasive pulmonary aspergillosis. <i>Mycoses</i> , 2015, 58, 368-374.	1.8	26
31	Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis. <i>Mycoses</i> , 2015, 58, 432-436.	1.8	53
32	Histoplasmosis and Blastomycosis in Solid Organ Transplant Recipients. <i>Journal of Fungi (Basel)</i> , 2015, 1, 10-18.	1.3	18
33	Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent. <i>Clinical Infectious Diseases</i> , 2015, 61, 1558-1565.	2.9	254
34	Treatment Options for Mucormycosis. <i>Current Treatment Options in Infectious Diseases</i> , 2015, 7, 142-154.	0.8	3
35	Role of Non-Culture-Based Tests, with an Emphasis on Galactomannan Testing for the Diagnosis of Invasive Aspergillosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 650-661.	0.8	60
36	Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients. <i>Infection and Drug Resistance</i> , 2012, 5, 9.	1.1	19

#	ARTICLE	IF	CITATIONS
37	Emerging opportunistic yeast infections. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 142-151.	4.6	659
38	Emerging moulds: epidemiological trends and antifungal resistance. <i>Mycoses</i> , 2011, 54, e666-e678.	1.8	84